BIOMERICA INC (BMRA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.31+4.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BMRA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Manage capital structure through private placements and unregistered equity sales to institutional and board investors.
Stated as a priority in 2 of last 2 quarters. The company executed private placements and equity sales agreements in 2026-Q2 and 2026-Q4 as disclosed in 8-K filings. This shows active capital allocation management consistent with stated priorities.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Entered into a Securities Purchase Agreement with institutional and board investors for private placement.”
“Entered into a Securities Purchase Agreement to sell shares of Diagnosis S.A.”
Focus on reducing operating losses and improving operating income over time.
Stated as a priority in 8 of last 8 quarters. Operating income remained negative, from -$1.57M in 2025-Q4 to -$1.53M in 2026-Q4, showing minimal improvement. Management continues to emphasize improving operating income but financials show limited progress.
“Operating income was negative $1.53 million, continuing focus on improvement.”
“Operating income was negative $1.30 million, management focused on improvement.”
“Operating income was negative $1.37 million, ongoing efforts to improve.”
“Operating income was negative $1.12 million, focus on reducing losses.”
“Operating income was negative $1.57 million, priority on improvement.”
“Operating income was negative $1.21 million, management targeting improvement.”
“Operating income was negative $993,000, focus on cost control.”
“Operating income was negative $1.37 million, ongoing cost management.”
Drive revenue growth through product sales and market expansion efforts.
Stated as a priority in 8 of last 8 quarters. Revenue declined from $1.81M in 2025-Q1 to $876K in 2026-Q4, indicating a downward trend. Despite management's consistent focus on revenue growth, the financials show declining revenue, reflecting limited progress.
“Revenue was $876,000, focus on enhancing revenue growth.”
“Revenue was $987,000, management focused on growth.”
“Revenue was $1.21 million, ongoing growth efforts.”
“Revenue was $1.38 million, focus on revenue enhancement.”
“Revenue was $749,000, growth remains a priority.”
“Revenue was $1.12 million, management targeting growth.”
“Revenue was $1.64 million, focus on increasing sales.”
“Revenue was $1.81 million, growth initiatives ongoing.”
Over the trailing year it converted 1.00x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.